Categories: NewsPharmaceutical

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) — XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ being held on May 20, 2024, in New York, NY.

Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will be featured in a fireside chat taking place at 11:00 AM ET.  The presentation can be accessed at https://bit.ly/4aQ74Y8.

XOMA’s presentations can also be accessed by visiting the investor relations section of the Company’s website at www.xoma.com.  A replay of each presentation will be available and archived on the site for 90 days after the event.

About XOMA Corporation
XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about the Company and its portfolio, please visit www.xoma.com.

XOMA Investor Contact   XOMA Media Contact
Juliane Snowden Kathy Vincent
XOMA Corporation  KV Consulting & Management
+1 646-438-9754   +1 310-403-8951
juliane.snowden@xoma.com kathy@kathyvincent.com

Staff

Recent Posts

Cosmo to Unveil First-of-its-Kind Clinical Study on the Use of GI Genius(TM) with Apple Vision Pro at Rush University Medical Center

Dublin, Ireland--(Newsfile Corp. - June 24, 2025) - Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced that…

15 minutes ago

TKSoftware Inc. Unveils ICONIC Pro: The All-In-One Medical Billing & Clearinghouse Solution

TKSoftware Inc. today launches ICONIC Pro, a unified, cloud–based platform that combines claims submission, electronic…

2 hours ago

Monarch Athletic Club: A Longevity Clinic Disguised as an Athletic Club

LOS ANGELES, June 23, 2025 /PRNewswire/ -- Monarch Athletic Club, the Los Angeles-based wellness disruptor…

2 hours ago

ZEISS Vision Care US Names Healthcare Industry Veteran Gary Rosenblum as President and Chief Executive Officer

Most Recently Serving as President for Oticon, a Division of Demant, Rosenblum Brings 30+ Years…

5 hours ago

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a company working to improve outcomes for…

8 hours ago

As Dangerous US Heat Wave Intensifies, AccuWeather Urges Public to Rely on Science-Backed RealFeel® Temperature for Accurate Danger Index

AccuWeather's RealFeel® Temperature is the only authentic formula-based metric—unlike 'Feels Like,' which lacks scientific credibility.Request…

8 hours ago